|Bid||41.50 x 1200|
|Ask||45.99 x 800|
|Day's Range||44.81 - 44.90|
|52 Week Range||29.50 - 78.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||79.50|
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief medical officer, will participate in a fireside chat during the Jefferies Gene Therapy/Editing Summit on Thursday, October 28, 2021 at 9:00 a.m. ET.
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
In this article, we discuss Cathie Wood stock portfolio: 10 newest stock picks this year. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood Stock Portfolio: 5 Newest Stock Picks This Year. Cathie Wood is a well-known star stock picker who manages disruptive innovation-focused portfolios through her ETFs. […]